Etoposide-induced hepatic injury: A potential complication of high-dose therapy

D. H. Johnson, F. A. Greco, S. N. Wolff

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6,800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.

Original languageEnglish (US)
Pages (from-to)1023-1024
Number of pages2
JournalCancer Treatment Reports
Volume67
Issue number11
StatePublished - 1983

Fingerprint

Etoposide
Liver
Wounds and Injuries
Chemical and Drug Induced Liver Injury
Hyperbilirubinemia
Therapeutics
Alkaline Phosphatase
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Etoposide-induced hepatic injury : A potential complication of high-dose therapy. / Johnson, D. H.; Greco, F. A.; Wolff, S. N.

In: Cancer Treatment Reports, Vol. 67, No. 11, 1983, p. 1023-1024.

Research output: Contribution to journalArticle

Johnson, D. H. ; Greco, F. A. ; Wolff, S. N. / Etoposide-induced hepatic injury : A potential complication of high-dose therapy. In: Cancer Treatment Reports. 1983 ; Vol. 67, No. 11. pp. 1023-1024.
@article{1e7f725d59a4423d91cc5f34a7627046,
title = "Etoposide-induced hepatic injury: A potential complication of high-dose therapy",
abstract = "Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6,800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.",
author = "Johnson, {D. H.} and Greco, {F. A.} and Wolff, {S. N.}",
year = "1983",
language = "English (US)",
volume = "67",
pages = "1023--1024",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Etoposide-induced hepatic injury

T2 - A potential complication of high-dose therapy

AU - Johnson, D. H.

AU - Greco, F. A.

AU - Wolff, S. N.

PY - 1983

Y1 - 1983

N2 - Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6,800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.

AB - Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6,800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.

UR - http://www.scopus.com/inward/record.url?scp=0021073168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021073168&partnerID=8YFLogxK

M3 - Article

C2 - 6315228

AN - SCOPUS:0021073168

VL - 67

SP - 1023

EP - 1024

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -